1829 / 1851
Toxicity of concurrent SRT and
antibody therapy
Anti-Her2 (trastuzumab)
Very limited available data
does not indicate
increased toxicity
of cranial SRT combined
with trastuzumab.
Data on trastuzumab and extra-cranial SRT is
lacking.
Kroeze S et al. Cancer Treatment Reviews 53 (2017) 25–37